Once-Daily Abacavir/Lamivudine and Ritonavir-Boosted Atazanavir for the Treatment of HIV-1 Infection in Antiretroviral-Naïve Patients: A 48-Week Pilot Study

REFERENCES

• Department of Heath and Human Services (DHHS). Guide-lines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. December 1,2007. http://aidsinfo.nih.gov/
   Google Scholar
• European AIDS Clinical Society (EACS). Guidelines for the clinical management and treatment of HIV-infected adults in Europe. December 2007. http://www.eacs.eu/guide/index.htm
   Google Scholar
• Dube MP, Stein JH, Aberg JA, et al. Guidelines for the evaluation and management of dyslipidemia in human im-munodeficiency virus (HIV)-infected adults receiving an-tiretroviral therapy: recommendations of the HIV Medical Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group. Clin Infect Dis. 2003;37:613–627.
   PubMed Web of Science ®Google Scholar
• Agarwala S, Russo R, Mummaneni V, et al. Steady-state pharmacokinetic (PK) interaction of atazanavir (ATV) with ritonavir (RTV) in healthy subjects. In: Abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Che-motherapy; 2002; San Diego, CA. Abstract H–1716.
   Google Scholar
• Badaro R, DeJesus E, Lazzarin A, et al. Efficacy and safety of atazanavir (ATV) with ritonavir (RTV) or saquinavir (SQV) versus lopinavir/ritonavir (LPV/RTV) in combination with tenofovir (TFV) and one NRTI in patients who have expe-rienced virologic failure to multiple HAART regimens: 16-week results from BMS A1424-045. In: 2nd IAS Conference on HIV Pathogenesis and Treatment; July 13–16, 2003; Paris, France. Abstract 118.
   Google Scholar
• Johnson M, Grinsztejn B, Rodriguez C, et al. Atazana-vir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures. AIDS. 2005;19:685–694.
   PubMed Web of Science ®Google Scholar
• Johnson M, Grinsztein B, Rodriguez C, et al. 96-week comparison of once-daily atazanavir/ritonavir and twice-daily lopinavir/ritonavir in patients with multiple virologic failures. AIDS. 2006;20:711–718.
   PubMed Web of Science ®Google Scholar
• Malan N, Krantz E, David N, et al. Efficacy and safety of atazanavir-based therapy in antiretroviral naive HIV-1 in-fected subjects, both with and without ritonavir: 48-week results from A1424-089. In: Program and abstracts of the 13th Conference on Retroviruses and Opportunistic In-fections; February 5–8, 2006; Denver, Colorado. Abstract 107LB.
   Google Scholar
• Smith K, Weinberg W, Dejesus E, et al. Once-daily rito-navir (100 mg) boosting of fosamprenavir (FPV/r) or ata-zanavir (ATZ/r) with tenofovir(TDF)/emtricitabine(FTC) in antiretroviral-naive HIV-infected patients: 48-week safety/ efficacy results from COL103952 (ALERT). In: Abstracts of the 4th IAS Conference on HIV Pathogenesis, Treatment and Prevention; July 22–25, 2007; Sydney, Australia. Ab-stract WEPEB023.
   Google Scholar
• Elion R, Cohen C, Ward D, et al. Evaluation of the efficacy, safety, pharmacokinetics (PK), adherence, and treatment satisfaction with boosted atazanavir (ATV/r) and fixed-dose emtricitabine/tenofovir DF (FTC/TDF) given once-daily (QD) in HIV infected, antiretroviral (ARV) naïve subjects: Final results of BATON. In: Abstracts of the 11th European AIDS Conference; October 24–27, 2007; Madrid, Spain. Abstract P7.3/20.
   Google Scholar
• McComsey GA, Ward DJ, Hessenthaler SM, et al. Im-provement in lipoatrophy associated with highly active antiretroviral therapy in human immunodeficiency virus-infected patients switched from stavudine to abacavir or zidovudine: the results of the TARHEEL study. Clin Infect Dis. 2004;38:263–270.
   PubMed Web of Science ®Google Scholar
• Martin A, Smith DE, Carr A, et al. Reversibility of lipoatro-phy in HIV-infected patients 2 years after switching from a thymidine analogue to abacavir: the MITOX Extension Study. AIDS. 2004;18:1029–1036.
   PubMed Web of Science ®Google Scholar
• Shlay JC, Visnegarwala F, Bartsch G, et al. Body composi-tion and metabolic changes in antiretroviral-naive patients randomized to didanosine and stavudine vs. abacavir and lamivudine. J Acquir Immune Defic Syndr 2005;38:147–155.
   PubMed Web of Science ®Google Scholar
• Podzamczer D, Ferrer E, Sanchez P, et al. Less lipoatro-phy and better lipid profile with abacavir as compared to stavudine: 96-week results of a randomized study. J Acquir Immune Defic Syndr 2007;44:139–147.
   PubMed Web of Science ®Google Scholar
• Hirsch MS, Brun-Vézinet F, Clotet B, et al. Antiretroviral drug resistance testing in adults infected with human im-munodeficiency virus type 1: 2003 recommendations of an International AIDS Society-USA Panel. Clin Infect Dis. 2003;37:113–128.
   PubMed Web of Science ®Google Scholar
• Levey AS, Coresh J, Greene T, et al. Using standardized serum creatinine values in the modification of diet in renal disease study question for estimating glomerular filtration rate. Ann Intern Med. 2006;145:247–254.
   PubMed Web of Science ®Google Scholar
• Katz A, Nambi SS, Mather K, et al. Quantitative insulin sen-sitivity check index: a simple, accurate method for assess-ing insulin sensitivity in humans. J Clin Endocrinol Metab. 2000;85:2402–2410.
   PubMed Web of Science ®Google Scholar
• Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and beta-cell func-tion from fasting plasma glucose and insulin concentra-tions in man. Diabetologia. 1985;28:412–419.
   PubMed Web of Science ®Google Scholar
• Eron J Jr, Yeni P, Gathe J Jr, et al. The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treat-ment of HIV infection over 48 weeks: a randomised non-inferiority trial. Lancet. 2006;368:476–482.
   PubMed Web of Science ®Google Scholar
• Jones CY, Wilson IB, Greenberg AS, et al. Insulin resistance in HIV-infected men and women in the Nutrition for Healthy Living Cohort. J Acquir Immune Defic Syndr 2005;40:202–211.
   PubMed Web of Science ®Google Scholar
• Jemsek JG, Arathoon E, Arlotti M, et al. Body fat and other metabolic effects of atazanavir and efavirenz, each admin-istered in combination with zidovudine plus lamivudine, in antiretroviral-naïve HIV-infected subjects. Clin Infect Dis. 2006;42:273–280.
   PubMed Web of Science ®Google Scholar
• McGrath D, Frederick D, Wirtz V, et al. Body composition changes in ART-naive subjects treated with atazanavir or atazanavir/ritonavir-based once-daily HAART: 48-week computer tomography and DEXA data. In: Program and abstracts of the 14th Conference on Retroviruses and Op-portunistic Infections, Los Angeles, California. Abstract 804.
   Google Scholar
• Wohl D, Lancaster T, Dejesus E, et al. Determination of body composition changes by total body DEXA after 48 weeks of treatment with once-daily fosamprenavir (FPV) boosted with two different doses of ritonavir(r) plus aba-cavir (ABC)/lamivudine(3TC): COL100758. In: Abstracts of the 4th IAS Conference on HIV Pathogenesis, Treatment and Prevention Sydney; July 22–25, 2007; Australia. Ab-stract TUPEB080.
   Google Scholar
• Cromwell WC, Otvos JD. Low-density lipoprotein particle number and risk for cardiovascular disease. Curr Athero-scler Rep. 2004;6:381–387.
   PubMedGoogle Scholar
• Otvos JD, Jeyarajah EJ, Cromwell WC. Measurement is-sues related to lipoprotein heterogeneity. Am J Cardiol. 2002;90:22i–29i.
   PubMed Web of Science ®Google Scholar
• Hughes AR, Mosteller M, Bansal AT, et al. Association of genetic variations in HLA-B region with hypersensitivity to abacavir in some, but not all, populations. Pharmacoge-nomics. 2004;5:203–211.
   PubMed Web of Science ®Google Scholar
• Reeves I, Churchill D, Fisher M. Clinical utility of HLA-B"5701 testing in a UK clinic cohort. Poster presentation at 13th Conference on Retroviruses and Opportunistic Infections; February 5–8, 2006; Denver, Colorado. Poster Abstract 667a.
   Google Scholar
• Rauch A, Nolan D, Martin A, et al. Prospective genetic screening decreases the incidence of abacavir hypersen-sitivity reaction in the western Australian HIV cohort study. Clin Infect Dis. 2006;43:99–102.
   PubMed Web of Science ®Google Scholar
• Melial S, Phillips E, Carosi G, et al. HLA-B"5701 screen-ing for hypersensitivity to abacavir. N Engl J Med. 2008; 358:568–579.
   PubMed Web of Science ®Google Scholar